Welcome to Weed Island

You can now buy THC products legally in Jersey outside of the medical framework, due to a loophole in CBD regulations.

Jersey, a British Crown Dependency, is rapidly emerging as a significant player in the European medical cannabis market. Northern Leaf, one of the island's largest licensed medical cannabis producers, operates a 100,000-square-foot facility, previously used for tomato cultivation. The company exported over 9,200 kilograms of medical marijuana in 2025, generating £8.4 million ($11.3 million) primarily to the UK and Germany. Jersey's unique regulatory environment, which allows for self-governance and rapid permit processing, combined with oversight from the UK's MHRA for quality standards, makes it an attractive location. The island legalized medical cannabis in 2019, and currently, 6% of its population is prescribed the substance, a rate significantly higher than in Germany or the UK. Despite export-only regulations for raw cannabis, there is a push to process and package final products on the island, pending potential law changes.

Jersey's strategic positioning as a self-governing Crown Dependency with streamlined regulatory processes, coupled with the UK MHRA's stringent quality control, establishes it as a trusted source for high-standard medical cannabis. The island's ambition to become a life sciences hub extends beyond cannabis, indicating a broader diversification strategy leveraging its unique administrative and regulatory advantages.

The burgeoning cannabis industry on Jersey, while promising significant economic growth, faces internal challenges including public perception and regulatory ambiguities. The tension between export-focused medical production and potential recreational sales via legal loopholes highlights the evolving landscape and the island's pivotal decisions regarding its future as a cannabis center.